Even as COVID-19 manufacturing dominates headlines, Swiss CDMO juggernaut Lonza is taking steps to keep the rest of its production arsenal competitive. The company's latest move? A nearly $1 billion investment to boost capacity at sites in Europe and the U.S.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,